Amlodipine

ID: amlodipine

Aliases: Norvasc

Type: compound

Route/form: oral

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, label

Linked sources: 3

Broad outcomes: Cardiovascular / lipids / blood pressure

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• L-type calcium channel blocker

Optimization domains

• hypertension
• angina
• cardiovascular

Research basis

• Amlodipine is a long-duration calcium-channel blocker with strong antihypertensive outcome context and practical relevance in BP-stack discussions.
• Its value in this repository is as a clean BP-control comparator, not as a performance enhancer.
• Long half-life and once-daily pharmacology make it clinically common when sustained BP lowering is needed.

Limits, risks, and missing evidence

• Peripheral edema, flushing, hypotension, gingival hyperplasia, and combination-therapy decisions are clinical issues.
• It does not directly address sympathetic physical anxiety or stimulant/AAS risk drivers.
• Adding it on top of other BP-lowering agents without monitoring can overshoot.

Risk flags

• approved drug
• blood pressure
• edema
• stack interactions

Linked papers, labels, and reviews

1. FDA label: Norvasc amlodipine besylate
   label / fda_amlodipine_label
   Official label.
2. DailyMed label: NORVASC amlodipine besylate tablet
   label / dailymed_norvasc_label
   Official US label for oral amlodipine hypertension and angina indications, dosing, contraindications, interactions, and adverse reactions.
3. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic: ALLHAT
   human_rct / pubmed_amlodipine_allhat_2002
   Large randomized outcomes trial including an amlodipine arm; anchors benefits and comparator risks in hypertension rather than stack lore.